Top 50 Biotech Startup Investors in Denmark in November 2024

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.

We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Oskare Capital is a venture capital firm.

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.

Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

ACME is a venture capital firm investing in iconic founders disrupting massive markets.

West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.

Nicholas Francis is Co-founder at framebunker

EIR Ventures is a new Life Science Venture Group in the Nordics.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.

Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures.&nbsp;<br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.

A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.

WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team

In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

The Yield Lab Europe is a €50m early stage Agrifood and Ag Tech fund which comprises an accelerator and a larger follow-on fund, investing in high tech companies with the potential to significant disrupt and improve our current systems of global food production, and to improve the environmental sustainability of the industry. The main fund invests€1m each into 10-12 companies over several follow on rounds, with the strongest accelerator companies expected to progress to the main fund. The Yield Lab Europe is also part of a global network of Agrifood Tech funds, with global headquarters in St Louis USA, and sister funds in LATAM and Singapore.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

Northzone is a multi-stage venture capital fund that seeks to invest in the healthcare, semiconductors, software, hardware, artificial intelligence, blockchain, and gaming industries.

Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.

The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

PINC invests in attractive start-ups leveraging four major consumer trends: Conscious Consumption, Holistic Health, Personalized Convenience, and Authentic Experiences.

Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.

Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.

The Footprint Firm is an advisory and investment company with a sole focus on sustainability.

About 30,000 products - 6,000 customers in roughly 160 countries. First synthesis of vanillin in 1874.

We invest in disruptive and encouraging Agri-Food tech and Food Loss companies, reshaping our food systems in order to solve the current & future problems of production.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.